{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30321197", "DateCompleted": {"Year": "2019", "Month": "03", "Day": "21"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "10", "Day": "15"}], "Language": ["eng"], "ELocationID": ["e0205340", "10.1371/journal.pone.0205340"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "13", "Issue": "10", "PubDate": {"Year": "2018"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "The small molecule rhodomyrtone suppresses TNF-\u03b1 and IL-17A-induced keratinocyte inflammatory responses: A potential new therapeutic for psoriasis.", "Pagination": {"StartPage": "e0205340", "MedlinePgn": "e0205340"}, "Abstract": {"AbstractText": ["Psoriasis is a common skin disease pathogenically driven by TNF and IL-17A-induced epidermal hyperproliferation and inflammatory responses. The ongoing need for new therapeutic agents for psoriasis has highlighted medicinal plants as sources of phytochemicals useful for treating psoriatic disease. Rhodomyrtone, a bioactive phytochemical from Rhodomyrtus tomentosa, has well-established anti-proliferative activities. This study assessed the potential of rhodomyrtone for curtailing TNF/IL-17A-driven inflammation. Stimulating human skin organ cultures with TNF+IL-17A to model the skin inflammation in psoriasis, we found that rhodomyrtone significantly decreased inflammatory gene expression and the expression and secretion of inflammatory proteins, assessed by qRT-PCR, immunohistochemistry and ELISA assays respectively. RNA-seq analysis of monolayer primary keratinocytes treated with IL-17A/TNF showed that rhodomyrtone inhibited 724/1587 transcripts >2-fold altered by IL-17A/TNF (p<0.01), a number of which were confirmed at the mRNA and protein level. Suggesting that rhodomyrtone acts by modulating MAP kinase and NF-\u03baB signaling pathways, rhodomyrtone inhibited TNF-induced ERK, JNK, p38, and NF-\u03baBp65 phosphorylation. Finally, assessing the in vivo anti-inflammatory potential of rhodomyrtone, we examined its effects on imiquimod-induced skin inflammation in mice, finding rhodomyrtone reversed imiquimod-induced skin hyperplasia and epidermal thickening (p< 0.001). Taken together, these results suggest that rhodomyrtone may be useful in preventing or slowing the progression of inflammatory skin disease."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}, {"Identifier": [], "Affiliation": "Department of Microbiology and Excellence Research Laboratory on Natural Products, Faculty of Science and Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai, Songkhla, Thailand."}], "LastName": "Chorachoo", "ForeName": "Julalak", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}], "LastName": "Lambert", "ForeName": "Sylviane", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}], "LastName": "Furnholm", "ForeName": "Teal", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}], "LastName": "Roberts", "ForeName": "Liza", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}], "LastName": "Reingold", "ForeName": "Laura", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand."}], "LastName": "Auepemkiate", "ForeName": "Sauvarat", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Microbiology and Excellence Research Laboratory on Natural Products, Faculty of Science and Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai, Songkhla, Thailand."}], "LastName": "Voravuthikunchai", "ForeName": "Supayang P", "Initials": "SP"}, {"Identifier": ["0000-0002-1313-9402"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Dermatology, University of Michigan School of Medicine, Ann Arbor, Michigan United States of America."}], "LastName": "Johnston", "ForeName": "Andrew", "Initials": "A"}], "GrantList": [{"GrantID": "K01 AR064765", "Acronym": "AR", "Agency": "NIAMS NIH HHS", "Country": "United States"}, {"GrantID": "T32 AR007197", "Acronym": "AR", "Agency": "NIAMS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Interleukin-17"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "0", "NameOfSubstance": "Xanthones"}, {"RegistryNumber": "0", "NameOfSubstance": "rhodomyrtone"}, {"RegistryNumber": "P1QW714R7M", "NameOfSubstance": "Imiquimod"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["toxicity"], "DescriptorName": "Imiquimod"}, {"QualifierName": ["chemically induced", "drug therapy", "genetics", "pathology"], "DescriptorName": "Inflammation"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Interleukin-17"}, {"QualifierName": ["drug effects", "pathology"], "DescriptorName": "Keratinocytes"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "NF-kappa B"}, {"QualifierName": [], "DescriptorName": "Organ Culture Techniques"}, {"QualifierName": ["chemically induced", "drug therapy", "genetics", "pathology"], "DescriptorName": "Psoriasis"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["drug effects", "pathology"], "DescriptorName": "Skin"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tumor Necrosis Factor-alpha"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Xanthones"}], "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003\u20132004. J Am Acad Dermatol. 2009;60(2):218\u201324. 10.1016/j.jaad.2008.09.022 .", "ArticleIdList": ["10.1016/j.jaad.2008.09.022", "PMC4762027", "19022533"]}, {"Citation": "Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66\u201373. 10.1016/j.jaut.2015.07.008 .", "ArticleIdList": ["10.1016/j.jaut.2015.07.008", "PMC4628849", "26215033"]}, {"Citation": "Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342\u201350. 10.1016/j.cyto.2014.12.014 .", "ArticleIdList": ["10.1016/j.cyto.2014.12.014", "PMC4437803", "25585875"]}, {"Citation": "Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2014;170(2):274\u2013303. 10.1111/bjd.12663 .", "ArticleIdList": ["10.1111/bjd.12663", "24131260"]}, {"Citation": "Leonardi CL, Romiti R, Tebbey PW. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin. 2015;33(1):111\u201325. 10.1016/j.det.2014.09.009 .", "ArticleIdList": ["10.1016/j.det.2014.09.009", "25412787"]}, {"Citation": "Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244\u201352. 10.1111/bjd.13343 .", "ArticleIdList": ["10.1111/bjd.13343", "25132294"]}, {"Citation": "Panthong A, Kanjanapothi D, Taylor WC. Ethnobotanical review of medicinal plants from Thai traditional books, Part I: Plants with anti-inflammatory, anti-asthmatic and antihypertensive properties. J Ethnopharmacol. 1986;18(3):213\u201328. .", "ArticleIdList": ["3546954"]}, {"Citation": "Panthong A, Kanjanapothi D, Taesotikul T, Taylor WC. Ethnobotanical review of medicinal plants from Thai traditional books, Part II: Plants with antidiarrheal, laxative and carminative properties. J Ethnopharmacol. 1991;31(2):121\u201356. .", "ArticleIdList": ["2023424"]}, {"Citation": "Srisuwan S, Tongtawe P, Srimanote P, Voravuthikunchai SP. Rhodomyrtone modulates innate immune responses of THP-1 monocytes to assist in clearing methicillin-resistant Staphylococcus aureus. PLoS One. 2014;9(10):e110321 10.1371/journal.pone.0110321 .", "ArticleIdList": ["10.1371/journal.pone.0110321", "PMC4199624", "25329066"]}, {"Citation": "Chorachoo J, Saeloh D, Srichana T, Amnuaikit T, Musthafa KS, Sretrirutchai S, et al. Rhodomyrtone as a potential anti-proliferative and apoptosis inducing agent in HaCaT keratinocyte cells. Eur J Pharmacol. 2016;772:144\u201351. 10.1016/j.ejphar.2015.12.005 .", "ArticleIdList": ["10.1016/j.ejphar.2015.12.005", "26687635"]}, {"Citation": "Hiranrat A, Mahabusarakam W. New acylphloroglucinols from the leaves of Rhodomyrtus tomentosa. Tetrahedron. 2008;64(49):11193\u20137. 10.1016/j.tet.2008.09.054", "ArticleIdList": ["10.1016/j.tet.2008.09.054"]}, {"Citation": "Salni D, Sargeant MV, Skelton BW, Soediro I, Sutisna M, White AH, et al. Rhodomyrtone, an antibotic from Rhodomyrtus tomentosa. Australian Journal of Chemistry. 2002;55(3):229\u201332."}, {"Citation": "Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. Journal of Investigative Dermatology. 2011;131(2):329\u201337. 10.1038/jid.2010.313", "ArticleIdList": ["10.1038/jid.2010.313", "PMC3094455", "20962853"]}, {"Citation": "Elder JT, Fisher GJ, Zhang Q-Y, Eisen D, Krust A, Kastner P, et al. Retinoic acid receptor gene expression in human skin. Journal of investigative dermatology. 1991;96(4):425\u201333.", "ArticleIdList": ["1848877"]}, {"Citation": "Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47 10.1093/nar/gkv007 .", "ArticleIdList": ["10.1093/nar/gkv007", "PMC4402510", "25605792"]}, {"Citation": "McCarthy DJ, Smyth GK. Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 2009;25(6):765\u201371. 10.1093/bioinformatics/btp053 .", "ArticleIdList": ["10.1093/bioinformatics/btp053", "PMC2654802", "19176553"]}, {"Citation": "Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320. Epub 2017/01/04. 10.1016/j.jaci.2016.08.056 .", "ArticleIdList": ["10.1016/j.jaci.2016.08.056", "PMC5494022", "28043870"]}, {"Citation": "Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677\u201387. 10.1038/jid.2010.340 .", "ArticleIdList": ["10.1038/jid.2010.340", "21085185"]}, {"Citation": "Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091\u20133. 10.1093/bioinformatics/btp101 .", "ArticleIdList": ["10.1093/bioinformatics/btp101", "PMC2666812", "19237447"]}, {"Citation": "Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353\u2013D61. Epub 2016/12/03. 10.1093/nar/gkw1092 .", "ArticleIdList": ["10.1093/nar/gkw1092", "PMC5210567", "27899662"]}, {"Citation": "van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836\u201345. 10.4049/jimmunol.0802999 .", "ArticleIdList": ["10.4049/jimmunol.0802999", "19380832"]}, {"Citation": "Gearing AJ, Fincham NJ, Bird CR, Wadhwa M, Meager A, Cartwright JE, et al. Cytokines in skin lesions of psoriasis. Cytokine. 1990;2(1):68\u201375. .", "ArticleIdList": ["2104215"]}, {"Citation": "Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252\u201362. 10.4049/jimmunol.1201505 .", "ArticleIdList": ["10.4049/jimmunol.1201505", "PMC3577967", "23359500"]}, {"Citation": "Wang CQ, Akalu YT, Suarez-Farinas M, Gonzalez J, Mitsui H, Lowes MA, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol. 2013;133(12):2741\u201352. 10.1038/jid.2013.237 .", "ArticleIdList": ["10.1038/jid.2013.237", "PMC3830693", "23732752"]}, {"Citation": "Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375(4):345\u201356. 10.1056/NEJMoa1512711 .", "ArticleIdList": ["10.1056/NEJMoa1512711", "27299809"]}, {"Citation": "Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338. 10.1056/NEJMoa1314258 .", "ArticleIdList": ["10.1056/NEJMoa1314258", "25007392"]}, {"Citation": "Di Cesare A, Fargnoli MC, Marinucci A, Peris K. Rationale for the development of speckled hyperpigmentation in the areas of psoriatic plaques after treatment with biologic agents. J Invest Dermatol. 2015;135(1):318\u201320. 10.1038/jid.2014.297 .", "ArticleIdList": ["10.1038/jid.2014.297", "25036050"]}, {"Citation": "Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167 Suppl 3:3\u201311. 10.1111/j.1365-2133.2012.11208.x .", "ArticleIdList": ["10.1111/j.1365-2133.2012.11208.x", "23082810"]}, {"Citation": "Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M, group Bs. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56\u201364. 10.1097/BOR.0b013e32835b1366 .", "ArticleIdList": ["10.1097/BOR.0b013e32835b1366", "23114587"]}, {"Citation": "Shivaji UN, Awasthi AK, Aherne R. Cutaneous Vasculitis Caused by Anti-Tumor Necrosis Factor Therapy: A Case Report. Clin Gastroenterol Hepatol. 2016;14(1):e1\u20132. 10.1016/j.cgh.2015.05.012 .", "ArticleIdList": ["10.1016/j.cgh.2015.05.012", "25998787"]}, {"Citation": "Kj\u00e6r TN, Thorsen K, Jessen N, Stenderup K, Pedersen SB. Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice. PloS one. 2015;10(5):e0126599 10.1371/journal.pone.0126599", "ArticleIdList": ["10.1371/journal.pone.0126599", "PMC4428792", "25965695"]}, {"Citation": "Sun Y, Zhang J, Huo R, Zhai T, Li H, Wu P, et al. Paeoniflorin inhibits skin lesions in imiquimod-induced psoriasis-like mice by downregulating inflammation. International immunopharmacology. 2015;24(2):392\u20139. 10.1016/j.intimp.2014.12.032", "ArticleIdList": ["10.1016/j.intimp.2014.12.032", "25576402"]}, {"Citation": "D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, H\u00f6lzel M, Ferring-Schmitt S, Sternberg S, et al. IL-36\u03b3 (IL-1F9) is a biomarker for psoriasis skin lesions. Journal of Investigative Dermatology. 2015;135(4):1025\u201332. 10.1038/jid.2014.532", "ArticleIdList": ["10.1038/jid.2014.532", "25525775"]}, {"Citation": "van den Bogaard EH, Tjabringa GS, Joosten I, Vonk-Bergers M, van Rijssen E, Tijssen HJ, et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. Journal of Investigative Dermatology. 2014;134(3):719\u201327. 10.1038/jid.2013.417", "ArticleIdList": ["10.1038/jid.2013.417", "24121402"]}, {"Citation": "Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et biophysica acta. 2010;1802(4):396\u2013405. 10.1016/j.bbadis.2009.12.009 .", "ArticleIdList": ["10.1016/j.bbadis.2009.12.009", "20079433"]}, {"Citation": "Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124(6):1275\u201383. 10.1111/j.0022-202X.2005.23735.x .", "ArticleIdList": ["10.1111/j.0022-202X.2005.23735.x", "15955104"]}, {"Citation": "Killeen MJ, Linder M, Pontoniere P, Crea R. NF-kappaB signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities. Drug Discov Today. 2014;19(4):373\u20138. 10.1016/j.drudis.2013.11.002 .", "ArticleIdList": ["10.1016/j.drudis.2013.11.002", "24246683"]}, {"Citation": "Herrington FD, Carmody RJ, Goodyear CS. Modulation of NK-\u03baB signaling as a therapeutic target in autoimmunity. J Biomol Screen. 2016;21(3):223\u201342. 10.1177/1087057115617456 .", "ArticleIdList": ["10.1177/1087057115617456", "26597958"]}, {"Citation": "Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity. 2014;47(2):77\u201394. 10.3109/08916934.2013.873413 .", "ArticleIdList": ["10.3109/08916934.2013.873413", "24437572"]}, {"Citation": "Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clinical and experimental immunology. 2014;176(1):1\u201310. 10.1111/cei.12248 .", "ArticleIdList": ["10.1111/cei.12248", "PMC3958149", "24313320"]}, {"Citation": "Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27(48):6245\u201351. 10.1038/onc.2008.301 .", "ArticleIdList": ["10.1038/onc.2008.301", "PMC3063296", "18931691"]}, {"Citation": "Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. European journal of immunology. 2013;43(12):3138\u201346. 10.1002/eji.201343801", "ArticleIdList": ["10.1002/eji.201343801", "24254490"]}, {"Citation": "Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. The Journal of Immunology. 2012;188(1):462\u20139. 10.4049/jimmunol.1102224", "ArticleIdList": ["10.4049/jimmunol.1102224", "22131335"]}, {"Citation": "Tortola L, Rosenwald E, Abel B, Blumberg H, Schafer M, Coyle AJ, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122(11):3965\u201376. 10.1172/JCI63451 .", "ArticleIdList": ["10.1172/JCI63451", "PMC3484446", "23064362"]}, {"Citation": "van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. The Journal of Immunology. 2009;182(9):5836\u201345. 10.4049/jimmunol.0802999", "ArticleIdList": ["10.4049/jimmunol.0802999", "19380832"]}]}], "History": [{"Year": "2018", "Month": "2", "Day": "5"}, {"Year": "2018", "Month": "9", "Day": "24"}, {"Year": "2018", "Month": "10", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "3", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "15"}], "PublicationStatus": "epublish", "ArticleIdList": ["30321197", "PMC6188632", "10.1371/journal.pone.0205340", "PONE-D-18-03945"]}}]}